Persisent ocular hypertension following intravitreal ranibizumab

  • Sophie J. Bakri
  • Colin A. McCannel
  • Albert O. Edwards
  • Darius M. Moshfeghi
Retinal Disorders

Abstract

Background

To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.

Methods

Case series.

Results

Four patients had high intraocular pressure after intravitreal ranibizumab 0.5 mg. Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2. In patient 4, it occurred several hours after the first ranibizumab injection. In all patients, the IOP increase was sustained across several visits, requiring control with topical glaucoma therapy, and in two cases the addition of a systemic carbonic anhydrase inhibitor. None of the patients had a previous history of glaucoma, ocular hypertension or IOP asymmetry and the IOP was as high as 30, 34, 46, and 50 mmHg in the four patients.

Conclusion

Severe and sustained ocular hypertension may occur after intravitreal ranibizumab. Although the mechanism of the pressure rise is unknown, all eyes in our series were controlled with medical therapy.

Keywords

Intraocular pressure Ranibizumab Intravitreal Lucentis Intravitreal Ocular hypertension Glaucoma Pressure increase Anti-VEGF 

References

  1. 1.
    Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J (2007) Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye Aug 10; [Epub ahead of print]Google Scholar
  2. 2.
    Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419–1431PubMedCrossRefGoogle Scholar
  3. 3.
    Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355(14):1432–1444PubMedCrossRefGoogle Scholar
  4. 4.
    Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351(27):2805–2816PubMedCrossRefGoogle Scholar
  5. 5.
    D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, Katz B, VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group (2006) Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 113(6):992–1001, e6PubMedCrossRefGoogle Scholar
  6. 6.
    Kubota T, Okabe H, Hisatomi T, Yamakiri K, Sakamoto T, Tawara A (2006) Ultrastructure of the trabecular meshwork in secondary glaucoma eyes after intravitreal triamcinolone acetonide. J Glaucoma 15(2):117–119PubMedCrossRefGoogle Scholar
  7. 7.
    Shinzato M, Yamashiro Y, Miyara N, Iwamatsu A, Takeuchi K, Umikawa M, Bayarjargal M, Kariya K, Sawaguchi S (2007) Proteomic analysis of the trabecular meshwork of rats in a steroid-induced ocular hypertension model: downregulation of type I collagen C-propeptides. Ophthalmic Res 39(6):330–337PubMedCrossRefGoogle Scholar
  8. 8.
    Leung YF, Tam PO, Lee WS, Lam DS, Yam HF, Fan BJ, Tham CC, Chua JK, Pang CP (2003) The dual role of dexamethasone on anti-inflammation and outflow resistance demonstrated in cultured human trabecular meshwork cells. Mol Vis 9:425–439PubMedGoogle Scholar
  9. 9.
    Rozsa FW, Reed DM, Scott KM, Pawar H, Moroi SE, Kijek TG, Krafchak CM, Othman MI, Vollrath D, Elner VM, Richards JE (2006) Gene expression profile of human trabecular meshwork cells in response to long-term dexamethasone exposure. Mol Vis 12:125–141PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Sophie J. Bakri
    • 1
  • Colin A. McCannel
    • 1
  • Albert O. Edwards
    • 1
  • Darius M. Moshfeghi
    • 2
  1. 1.Department of OphthalmologyMayo ClinicRochesterUSA
  2. 2.Department of OphthalmologyStanford UniversityPalo AltoUSA

Personalised recommendations